摘要
目的探讨对中晚期原发性肝癌(HCC)患者采用超选择性肝动脉化疗栓塞术(S-TACE)联合阿帕替尼治疗的效果和安全性。方法将近年来的72例中晚期HCC患者分成两组,对照组采用S-TACE治疗,观察组采用S-TACE联合阿帕替尼治疗;观察两组的肿瘤血管炎症因子、肝功能的变化,治疗效果和安全性指标。结果治疗前,两组的VEGFR2、MMP-9和caspase-8等肿瘤血管因子指标水平,以及AFP-L3、ALT和LDH等肝功能指标水平比较,无统计学意义(P>0.05);疗程结束后,观察组的肿瘤血管因子和肝功能指标水平均较对照组改善,有统计学意义(P<0.05)。观察组的ORR和DCR高于对照组,MTTP和MOS大于对照组,有统计学意义(P<0.05)。两组的栓塞后综合征比较无统计学意义(P>0.05);观察组的药物不良反应高于对照组,有统计学意义(P>0.05)。结论对中晚期HCC患者采用STACE联合阿帕替尼治疗,可抑制肿瘤血管再生,改善肝脏功能,提高临床获益率,安全性较高。
Objective To investigate the efficacy and safety of super-selective hepatic arterial chemoembolization(STACE)combined with apatinib in patients with advanced primary liver cancer(HCC).Methods In recent years,72 patients with advanced HCC were divided into two groups.The control group was treated with S-TACE,and the observation group was treated with S-TACE combined with apatinib.The changes of tumor vascular inflammatory factors,liver function,therapeutic effect and safety indexes in the two groups were observed.Results Before treatment,the levels of tumor vascular factors such as VEGFR2,mmp-9 and caspase-8,as well as the levels of liver function indexes such as AFP-L3,ALT,and LDH in the two groups were not statistically significant(P>0.05).After the treatment,the levels of tumor vascular factors and liver function indexes in the observation group were improved compared with those in the control group,which was statistically significant(P<0.05).The ORR and DCR in the observation group were higher than those in the control group,while MTTP and MOS were higher than those in the control group,which was statistically significant(P<0.05).There was no significant difference in the postembolization syndrome between the two groups(P>0.05).The adverse drug reactions in the observation group were higher than those in the control group,which was statistically significant(P>0.05).Conclusion For patients with advanced HCC,S-TACE combined with apatinib therapy can inhibit tumor angiogenesis,improve liver function,improve clinical benefit rate and provide high safety.
作者
徐新宝
殷杰
吉浩明
钱俐
XU Xin-bao;YIN Jie;JI Hao-ming;QIAN Li(Department of General Surgery,Hai’an Hospital Affiliated to Nantong University,Jiangsu 226600,China;Department of Oncology,Affiliated Hospital of Nantong University,Jiangsu 226600,China)
出处
《肝脏》
2020年第9期933-936,共4页
Chinese Hepatology
基金
南通市2017年度市级科技计划项目(MS12017017)。
